Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Erlotinib (Tarceva™)

Last Updated: 01/30/20

Status: Currently a NF2 Clinical Trial

Chemical Structure, Erlotinib

Trade Name:
Tarceva, 183321-74-6, CHEBI:114785,
Pharmaceutical Companies:
Genetech, Roche, and OSI Pharmaceuticals/Astellas
Legal Status:
℞ - Prescription Only
Administered By:
Pill - Oral
Tumor Target:
Intracranial Schwannoma
Protein Target:
TKI Inhibitor

NF2 Trial

  • Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 - www.ClinicalTrials.gov
  • A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-Small-Cell Lung Cancer (NSCLC) - www.ClinicalTrials.gov
  • Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib - www.ClinicalTrials.gov
  • Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy - www.ClinicalTrials.gov

Side Effects


Side Effects may Increase, tell your Doctor if you experience any of the following:

  • Diarrhea
  • Loss of Appetite
  • Nausea
  • Vomiting
  • Heartburn
  • Gas
  • Constipation
  • Stomach Pain
  • Mouth Sores
  • Weight Loss
  • Extreme Tiredness
  • Headache
  • Bone or Muscle Pain
  • Depression
  • Anxiety
  • Numbness, Burning, or Tingling of the Hands or Feet
  • Swelling of the Arms, Hands, Feet, Ankles, or Lower Legs
  • Darkening of Skin
  • Hair Loss
  • Change in Appearance of Hair and Nails

Serious Side Effects

  • Shortness of Breath
  • Cough
  • Fever or Chills
  • Chest Pain or Pressure
  • Pain in the Arms, Neck, or Upper Back
  • Rapid, Irregular, or Pounding Heartbeat
  • Slow or Difficult Speech
  • Dizziness or Faintness
  • Weakness or Numbness of an Arm or Leg
  • Unusual Bruising or Bleeding
  • Black and Tarry or Bloody Stools
  • Bloody Vomit or that looks like Coffee Grounds
  • Dry Mouth
  • Decreased Urination
  • Dark Urine
  • Pale or Yellow Skin
  • Redness, Warmth, Pain, Tenderness, or Swelling in One Leg
  • Skin Issues -
    1. Rash (may look like acne and may affect the skin on the face, upper chest, or back
    2. Blistering
    3. Peeling
    4. Dry
    5. Cracked Skin
    6. Itching
    7. Tenderness
    8. Burning
  • Eye Issues -
    1. Dry Eyes
    2. Red Eyes
    3. Eye Pain
    4. Irritated Eyes
    5. Blurred Vision
    6. Sunken Eyes
    7. Growth of Eyelashes on the inside of the eyelid


  1. Van, JJ Gompel, et al. "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas." Neurosurgery (2017). Source: http://europepmc.org/abstract/med/29309638 | DOI: 10.1093/neuros/nyx516
  2. Benhamouche, Samira, et al. "Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver." Genes & development 24.16 (2010): 1718-1730. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030413/ | DOI: 10.1101/gad.1964810
  3. Plotkin, Scott R., et al. "Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients." Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 31.7 (2010): 1135. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030413/#R10 | DOI: 10.1097/MAO.0b013e3181eb328a
  4. Plotkin, Scott R., et al. "Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy." Nature Reviews Clinical Oncology 5.8 (2008): 487. Source: https://www.nature.com/articles/ncponc1157 | DOI: 10.1038/ncponc1157
  5. Goutagny, Stéphane, Marco Giovannini, and Michel Kalamarides. "A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas." Journal of neuro-oncology 133.2 (2017): 443-445. Source: https://link.springer.com/article/10.1007/s11060-017-2447-3
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021